Left Ventricular hypertrophy (LVH) regression with Dapagliflozin in Diabetic and Hypertensive patients.

Authors

  • Khaled Refaat Abd El Meguid, MD, Hesham Boshra Elsayed, MD, Kyrillos Paules Saleep, Ehab Elyamani, MD Author

DOI:

https://doi.org/10.48047/b3j9wt59

Keywords:

LVH, Dapagliflozin, Diabetes mellitus, Hypertension, LVMI

Abstract

Background: Left ventricular hypertrophy (LVH) is a significant predictor of cardiovascular events, including myocardial infarction and heart failure. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has shown potential for LVH regression through mechanisms such as afterload reduction and anti inflammatory effects. This study evaluates the impact of dapagliflozin on LVH regression in diabetic and hypertensive patients. 

Downloads

Download data is not yet available.

References

Liu, W., Y. Higashikuni, and M. Sata, Optimizing antihypertensive therapy in patients with diabetes mellitus. Hypertens Res, 2023. 46(3): p. 797

Levy, D., et al., Prognostic implications of echocardiographicallyleft ventricular mass determined in the Framingham Heart Study. N Engl J

Med, 1990. 322(22): p. 1561-6.

Downloads

Published

2025-02-03

How to Cite

Khaled Refaat Abd El Meguid, MD, Hesham Boshra Elsayed, MD, Kyrillos Paules Saleep, Ehab Elyamani, MD. (2025). Left Ventricular hypertrophy (LVH) regression with Dapagliflozin in Diabetic and Hypertensive patients . Cuestiones De Fisioterapia, 54(3), 114-128. https://doi.org/10.48047/b3j9wt59